You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMetaxalone
Accession NumberDB00660  (APRD00514)
TypeSmall Molecule
GroupsApproved
DescriptionMetaxalone (marketed by King Pharmaceuticals under the brand name Skelaxin®) is a muscle relaxant used to relax muscles and relieve pain caused by strains, sprains, and other musculoskeletal conditions. Its exact mechanism of action is not known, but it may be due to general central nervous system depression. It is considered to be a moderately strong muscle relaxant, with relatively low incidence of side effects. Skelaxin comes in an 800 mg scored tablet. It previously came in both 400 mg and 800 mg tablets. The 400 mg tablet has been discontinued. Possible side effects include nausea, vomiting, drowsiness and CNS side effects such as dizziness, headache, and irritability.
Structure
Thumb
Synonyms
Metassalone
Metaxalon
Metaxalona
Metaxalonum
Skelaxin
External Identifiers
  • AHR 438
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Metaxalonetablet800 mg/1oralSTAT Rx USA LLC2007-11-01Not applicableUs
Metaxalonetablet800 mg/1oralCore Pharma, Llc2007-11-01Not applicableUs
Metaxalonetablet800 mg/1oralBlenheim Pharmacal, Inc.2010-05-20Not applicableUs
Metaxalonetablet800 mg/1oralPreferred Pharmaceuticals, Inc.2014-02-14Not applicableUs
Metaxalonetablet800 mg/1oralDIRECT RX2014-01-01Not applicableUs
Metaxalonetablet800 mg/1oralCarilion Materials Management2007-11-01Not applicableUs
Metaxalonetablet800 mg/1oralPd Rx Pharmaceuticals, Inc.2007-11-01Not applicableUs
Metaxalonetablet800 mg/1oralUnit Dose Services2007-11-01Not applicableUs
Metaxalonetablet800 mg/1oralSt. Marys Medical Park Pharmacy2011-01-30Not applicableUs
Metaxalonetablet800 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-12-06Not applicableUs
Metaxalonetablet800 mg/1oralbryant ranch prepack2007-11-01Not applicableUs
Metaxalonetablet800 mg/1oralDispensing Solutions, Inc.2007-11-01Not applicableUs
Metaxalonetablet800 mg/1oralPd Rx Pharmaceuticals, Inc.2007-11-01Not applicableUs
Metaxalonetablet800 mg/1oralNorthwind Pharmaceuticals2014-04-01Not applicableUs
Metaxalonetablet800 mg/1oralRebel Distributors Corp2007-11-01Not applicableUs
Metaxalonetablet800 mg/1oralbryant ranch prepack2007-11-01Not applicableUs
Metaxalonetablet800 mg/1oralREMEDYREPACK INC.2012-03-29Not applicableUs
Metaxalonetablet800 mg/1oralSTAT Rx USA LLC2007-11-01Not applicableUs
Metaxalonetablet800 mg/1oralH.J. Harkins Company, Inc.2007-11-01Not applicableUs
Skelaxintablet800 mg/1oralPhysicians Total Care, Inc.2003-01-30Not applicableUs
Skelaxintablet800 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-12-14Not applicableUs
Skelaxintablet800 mg/1oralRebel Distributors Corp1962-08-13Not applicableUs
Skelaxintablet800 mg/1oralCardinal Health2002-08-30Not applicableUs
Skelaxintablet800 mg/1oralBlenheim Pharmacal, Inc.2010-03-15Not applicableUs
Skelaxintablet800 mg/1oralPd Rx Pharmaceuticals, Inc.2002-08-30Not applicableUs
Skelaxintablet800 mg/1oralSTAT Rx USA LLC2002-08-30Not applicableUs
Skelaxintablet800 mg/1oralPreferred Pharmaceuticals, Inc2003-01-30Not applicableUs
Skelaxintablet800 mg/1oralPfizer Laboratories Div Pfizer Inc2002-08-30Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Metaxalltablet800 mg/1oralSircle Laboratories, Llc2015-09-25Not applicableUs
Metaxalonetablet800 mg/1oralAmneal Pharmaceuticals of New York, LLC2013-05-31Not applicableUs
Metaxalonetablet800 mg/1oralAmerican Health Packaging2013-12-18Not applicableUs
Metaxalonetablet800 mg/1oralEon Labs, Inc.2010-03-31Not applicableUs
Metaxalonetablet800 mg/1oralDIRECT RX2015-01-01Not applicableUs
Metaxalonetablet400 mg/1oralCore Pharma, Llc2015-03-31Not applicableUs
Metaxalonetablet800 mg/1oralAv Kare, Inc.2015-05-22Not applicableUs
Metaxalonetablet800 mg/1oralPhysicians Total Care, Inc.2010-04-07Not applicableUs
Metaxalonetablet800 mg/1oralKeltman Pharmaceuticals Inc.2008-06-25Not applicableUs
Metaxalonetablet800 mg/1oralBlenheim Pharmacal, Inc.2013-09-11Not applicableUs
Metaxalonetablet800 mg/1oralProficient Rx LP2013-05-31Not applicableUs
Metaxalonetablet800 mg/1oralAv Pak2015-03-13Not applicableUs
Metaxalonetablet800 mg/1oralClinical Solutions Wholesale2013-05-31Not applicableUs
Metaxalonetablet800 mg/1oralRebel Distributors Corp.2010-03-31Not applicableUs
Metaxalonetablet800 mg/1oralPreferred Pharmaceuticals, Inc.2015-01-06Not applicableUs
Metaxalonetablet800 mg/1oralAmneal Pharmaceuticals, LLC2013-05-31Not applicableUs
Metaxalonetablet800 mg/1oralNorthwind Pharmaceuticals2014-02-12Not applicableUs
Metaxalonetablet800 mg/1oralGemini Laboratories, LLC2015-12-30Not applicableUs
Metaxalonetablet800 mg/1oralAidarex Pharmaceuticals LLC2013-05-31Not applicableUs
Metaxalonetablet800 mg/1oralBlue Point Laboratories2014-04-22Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII1NMA9J598Y
CAS number1665-48-1
WeightAverage: 221.2524
Monoisotopic: 221.105193351
Chemical FormulaC12H15NO3
InChI KeyInChIKey=IMWZZHHPURKASS-UHFFFAOYSA-N
InChI
InChI=1S/C12H15NO3/c1-8-3-9(2)5-10(4-8)15-7-11-6-13-12(14)16-11/h3-5,11H,6-7H2,1-2H3,(H,13,14)
IUPAC Name
5-(3,5-dimethylphenoxymethyl)-1,3-oxazolidin-2-one
SMILES
CC1=CC(OCC2CNC(=O)O2)=CC(C)=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenol ethers. These are aromatic compounds containing an ether group substituted with a benzene ring.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenol ethers
Direct ParentPhenol ethers
Alternative Parents
Substituents
  • Phenol ether
  • Alkyl aryl ether
  • Oxazolidinone
  • Oxazolidine
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Monocarboxylic acid or derivatives
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of painful peripheral musculoskeletal conditions and spasticity from upper motor neuron syndromes.
PharmacodynamicsMetaxalone is a skeletal muscle relaxant indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions. The mode of action of this drug has not been clearly identified, but may be related to its sedative properties. Metaxalone does not directly relax tense skeletal muscles in man.
Mechanism of actionThe mechanism of action of metaxalone in humans has not been established, but may be due to general central nervous system depression.
Related Articles
AbsorptionThe absolute bioavailability of metaxalone from Skelaxin tablets is not known.
Volume of distribution
  • 800 L
Protein bindingNot Available
Metabolism

Probably hepatic.

Route of eliminationMetaxalone is metabolized by the liver and excreted in the urine as unidentified metabolites.
Half life9.2 (+/- 4.8) hours
Clearance
  • 68 +/- 50 L/h [Subjects received 1×400mg tablet under fasted conditions]
  • 66 +/- 51 L/h [Subjects received 2×400 mg tablets under fasted conditions]
ToxicityLD50=775mg/kg (Rat, oral); LD50=1690 mg/kg (Mouse, oral). When determining the LD50 in rats and mice, progressive sedation, hypnosis and finally respiratoryfailure were noted as the dosage increased. In dogs, no LD50 could be determined as the higher doses produced an emetic action in 15 to 30 minutes.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9747
Caco-2 permeable+0.5076
P-glycoprotein substrateNon-substrate0.7072
P-glycoprotein inhibitor INon-inhibitor0.8309
P-glycoprotein inhibitor IINon-inhibitor0.906
Renal organic cation transporterNon-inhibitor0.8464
CYP450 2C9 substrateNon-substrate0.8154
CYP450 2D6 substrateNon-substrate0.7182
CYP450 3A4 substrateNon-substrate0.5649
CYP450 1A2 substrateInhibitor0.6863
CYP450 2C9 inhibitorNon-inhibitor0.7448
CYP450 2D6 inhibitorNon-inhibitor0.7733
CYP450 2C19 inhibitorNon-inhibitor0.6471
CYP450 3A4 inhibitorNon-inhibitor0.911
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.797
Ames testNon AMES toxic0.6074
CarcinogenicityNon-carcinogens0.9312
BiodegradationNot ready biodegradable0.9544
Rat acute toxicity2.4250 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9319
hERG inhibition (predictor II)Non-inhibitor0.913
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Sandoz inc
  • King pharmaceuticals inc
  • Elan Corporation
Packagers
Dosage forms
FormRouteStrength
Tabletoral400 mg/1
Tabletoral800 mg/1
Prices
Unit descriptionCostUnit
Metaxalone 800 mg tablet3.88USD tablet
Skelaxin 800 mg tablet3.84USD tablet
Skelaxin 400 mg tablet0.84USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6407128 No2001-12-032021-12-03Us
US7122566 No2006-02-062026-02-06Us
US7714006 No2001-12-032021-12-03Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point122 °CPhysProp
logP2.3Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.28 mg/mLALOGPS
logP1.63ALOGPS
logP2.37ChemAxon
logS-2.2ALOGPS
pKa (Strongest Acidic)13.14ChemAxon
pKa (Strongest Basic)-4.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area47.56 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity59.32 m3·mol-1ChemAxon
Polarizability23.74 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Spiridon Spireas, “Bioavailable compositions of metaxalone and processes for producing the same.” U.S. Patent US20050276844, issued December 15, 2005.

US20050276844
General References
  1. See S, Ginzburg R: Choosing a skeletal muscle relaxant. Am Fam Physician. 2008 Aug 1;78(3):365-70. [PubMed:18711953 ]
  2. Elenbaas JK: Centrally acting oral skeletal muscle relaxants. Am J Hosp Pharm. 1980 Oct;37(10):1313-23. [PubMed:6999895 ]
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (124 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Metaxalone.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Metaxalone.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Metaxalone.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Metaxalone.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Metaxalone.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Metaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Metaxalone.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Metaxalone.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Metaxalone.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Metaxalone.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Metaxalone.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Metaxalone.
AmoxapineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Metaxalone.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Metaxalone.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Metaxalone.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Metaxalone.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Metaxalone.
AzelastineMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Metaxalone.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Metaxalone.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Metaxalone.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Metaxalone.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Metaxalone.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Metaxalone is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.
BrimonidineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Metaxalone.
BrompheniramineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Metaxalone.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Metaxalone.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Metaxalone.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Metaxalone.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Metaxalone.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Metaxalone.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Metaxalone.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Metaxalone.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Metaxalone.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Metaxalone.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Metaxalone.
CarbinoxamineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Metaxalone.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Metaxalone.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Metaxalone.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Metaxalone.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Metaxalone.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Metaxalone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Metaxalone.
ChlorphenamineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Chlorphenamine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Metaxalone.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Metaxalone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Metaxalone.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Metaxalone.
CitalopramThe risk or severity of adverse effects can be increased when Metaxalone is combined with Citalopram.
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Metaxalone.
ClidiniumThe risk or severity of adverse effects can be increased when Metaxalone is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Metaxalone.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Metaxalone.
ClomipramineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Metaxalone is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Metaxalone.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Metaxalone.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Metaxalone.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Metaxalone.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Metaxalone.
CyclizineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Metaxalone.
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Metaxalone.
DantroleneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Metaxalone.
DapoxetineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Dapoxetine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Metaxalone.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Metaxalone.
DesipramineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Metaxalone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Metaxalone.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Metaxalone.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Metaxalone.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Metaxalone.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Metaxalone.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Metaxalone.
DifenoxinThe risk or severity of adverse effects can be increased when Metaxalone is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Metaxalone.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Metaxalone.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Metaxalone.
DimenhydrinateThe risk or severity of adverse effects can be increased when Metaxalone is combined with Dimenhydrinate.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Metaxalone.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Metaxalone.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Metaxalone.
DoxepinThe risk or severity of adverse effects can be increased when Metaxalone is combined with Doxepin.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.
DoxylamineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Metaxalone.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Metaxalone.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Metaxalone.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Metaxalone.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Metaxalone.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Metaxalone.
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Metaxalone.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Metaxalone.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Metaxalone.
EscitalopramThe risk or severity of adverse effects can be increased when Metaxalone is combined with Escitalopram.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Metaxalone.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Metaxalone.
EthanolMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Metaxalone.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Metaxalone.
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Metaxalone.
EthotoinThe risk or severity of adverse effects can be increased when Metaxalone is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Metaxalone.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Metaxalone.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Metaxalone.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Metaxalone.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Metaxalone.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Metaxalone.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Metaxalone.
EtoperidoneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Metaxalone.
EzogabineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Metaxalone is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Metaxalone.
FenfluramineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Metaxalone.
FexofenadineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Metaxalone is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Metaxalone.
FlunarizineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Metaxalone.
FluoxetineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Metaxalone.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Metaxalone.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Metaxalone.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Metaxalone.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Metaxalone.
FluvoxamineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Fluvoxamine.
FosphenytoinThe risk or severity of adverse effects can be increased when Metaxalone is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Metaxalone.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Metaxalone.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Metaxalone is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Metaxalone.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Metaxalone.
GuanfacineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Metaxalone.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Metaxalone.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Metaxalone.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Metaxalone.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Metaxalone.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Metaxalone.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Metaxalone.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.
HydroxyzineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Hydroxyzine.
IloperidoneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Iloperidone.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Metaxalone.
IndalpineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Indalpine.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Metaxalone.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Metaxalone.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Metaxalone.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Metaxalone.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Metaxalone.
LevetiracetamThe risk or severity of adverse effects can be increased when Metaxalone is combined with Levetiracetam.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Metaxalone.
LevocabastineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Metaxalone is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Metaxalone.
LevomilnacipranThe risk or severity of adverse effects can be increased when Metaxalone is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Metaxalone.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Metaxalone.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Metaxalone.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Metaxalone.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Metaxalone.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Metaxalone.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Metaxalone.
Lu AA21004The risk or severity of adverse effects can be increased when Metaxalone is combined with Lu AA21004.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Metaxalone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Metaxalone is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Maprotiline.
MeclizineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Metaxalone.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Metaxalone.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Metaxalone.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Metaxalone.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Metaxalone.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Metaxalone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Metaxalone.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Metaxalone.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Metaxalone.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Metaxalone.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Metaxalone.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Metaxalone.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Metaxalone.
MethsuximideThe risk or severity of adverse effects can be increased when Metaxalone is combined with Methsuximide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Metaxalone.
MetyrosineMetaxalone may increase the sedative activities of Metyrosine.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Metaxalone.
MilnacipranThe risk or severity of adverse effects can be increased when Metaxalone is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.
MirtazapineMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Metaxalone.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Metaxalone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Metaxalone.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.
NabiloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Nabilone.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Metaxalone.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Metaxalone.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Metaxalone.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Metaxalone.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Metaxalone.
OlanzapineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Olanzapine.
OlopatadineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Metaxalone.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Metaxalone.
OrphenadrineMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Metaxalone.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Metaxalone.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Metaxalone.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Metaxalone.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Metaxalone.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Metaxalone.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Metaxalone.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Metaxalone.
ParaldehydeMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Metaxalone.
ParoxetineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Paroxetine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Metaxalone.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Metaxalone.
PerampanelThe risk or severity of adverse effects can be increased when Metaxalone is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Metaxalone.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Metaxalone.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Metaxalone.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Metaxalone.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Metaxalone.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Metaxalone.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Metaxalone.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Metaxalone.
PipotiazineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Metaxalone is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Metaxalone is combined with Pomalidomide.
PramipexoleMetaxalone may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Metaxalone.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Metaxalone.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Metaxalone.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Metaxalone.
PrimidoneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Metaxalone.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Metaxalone.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Metaxalone.
PromethazineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Promethazine.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Metaxalone.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Metaxalone.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Metaxalone.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Metaxalone.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Metaxalone.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Metaxalone.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Metaxalone.
RamelteonThe risk or severity of adverse effects can be increased when Metaxalone is combined with Ramelteon.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Metaxalone.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Metaxalone.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Metaxalone.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Metaxalone.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Metaxalone.
RopiniroleMetaxalone may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Metaxalone.
RotigotineMetaxalone may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Metaxalone.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Metaxalone.
ScopolamineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Metaxalone.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Metaxalone.
SertralineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Metaxalone.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Metaxalone.
StiripentolThe risk or severity of adverse effects can be increased when Metaxalone is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Metaxalone.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Metaxalone.
SuvorexantThe risk or severity of adverse effects can be increased when Metaxalone is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Metaxalone is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Metaxalone is combined with Tasimelteon.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Metaxalone.
TetrabenazineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Metaxalone.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Metaxalone.
ThalidomideMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Metaxalone.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Metaxalone.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Metaxalone.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Metaxalone.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Metaxalone.
TiagabineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Tiagabine.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Metaxalone.
TizanidineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Tizanidine.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Metaxalone.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Metaxalone.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Metaxalone.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Metaxalone.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Metaxalone.
TrazodoneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Metaxalone.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Metaxalone.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Metaxalone.
TrimipramineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Metaxalone.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Metaxalone.
VigabatrinThe risk or severity of adverse effects can be increased when Metaxalone is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Vilazodone.
VortioxetineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Metaxalone.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Metaxalone.
ZiconotideThe risk or severity of adverse effects can be increased when Metaxalone is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Metaxalone is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Metaxalone.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Metaxalone.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Metaxalone.
ZonisamideThe risk or severity of adverse effects can be increased when Metaxalone is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Metaxalone.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Metaxalone.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Metaxalone.
Food InteractionsNot Available
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 30, 2016 02:25